Xultophy® 100/3.6 is a once-daily combination of a basal insulin (insulin degludec) and a GLP-1 receptor agonist (liraglutide) for adults with type 2 diabetes
| Manufacturer | Alkem Laboratories |
|---|---|
| Brand Name | Xultophy |
| Dosage | as prescribed |
| Dosage Form | Solution for injection |
| Size | 300 units per pen Each prefilled disposable pen contains 300 units of Xultophy® 100/3.6 (300 units insulin degludec/10.8 mg liraglutide) |
| Active Ingredients | insulin degludec and liraglutide |
| Side Effects | Serious hypersensitivity reactions including anaphylactic reactions and angioedema and thyroid tumor have been reported with liraglutide, one of its components. |
Write Your Own Review